Possible Product Launches for 2011

Product Anticipated Ship Date Brand Sales Additional information
Caduet  11/30/2011 $340 million Ranbaxy will have a license to sell generic version Caduet in the U.S. effective November 30, 2011,
Femara 6/3/2011 $533 million Mylan settled, can market before the patent expires
Levaquin 6/20/2011 $1.5 billion Teva has been granted final approval and first-to-file status for Levofloxacin 750mg.
Lipitor 11/30/2011 $7.6 billion Ranbaxy will have a license to sell generic version Lipitor in the U.S. effective November 30, 2011. Ranbaxy 180 day exclusive. Watson will have the AG
Nasacort AQ 6/15/2011 Under the terms of the settlement, Barr will be able to market the ANDA product under license from Sanofi-Aventis as early as June 15, 2011
Quixin end of March $2 million Hi-Tech has final approval and is planning to lauch then end of March
Solodyn 11/1/2011 $340 million IMPAX Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic versions of SOLODYN(R) (minocycline HCI) 45mg, 90mg and 135mg Extended-release Tablets. Medicis markets SOLODYN(R) for the treatment of moderate-to-severe acne. As previously announced on December 1, 2008, IMPAX and Medicis entered into a Settlement and License Agreement, under which IMPAX has a license to market its generic versions of SOLODYN(R) 45mg, 90mg and 135mg through Global Pharmaceuticals, IMPAX’s generic division, under the SOLODYN(R) intellectual property rights belonging to Medicis, no later than November 2011. Medicis Pharmaceutical Corp. said it settled a lawsuit again Sandoz, Sandoz will not ship any more of its version of the drug until November 2011
Tricor 3/28/2011 $1.6 billion The licensing agreement paves the way for Teva to launch a generic version no sooner than March 28, 2011. Under certain unspecified circumstances, Teva might not receive such rights until July 1, 2012, Abbott said in a U.S. securities filing.
Uroxatral 6/18/2011 $168 million Apotex, Aurobindo, Invagen, Mylan, Sun, Teva, Torrent and Wockhardt have tentative approval
Vfend February $164 million Mylan and Greenstone
Xalatan 3/22/2011 $603 million Multiple manufacturers expected to launch
Zyprexa 10/23/2011 $2.5 billion Teva, Mylan and Sandoz have tentative approval
All information is believed to be accurate, but is subject to correction and change
This entry was posted in Industry Updates. Bookmark the permalink.

Comments are closed.